A Fully Integrated Cancer Company.
|
|
- Michael Lynch
- 5 years ago
- Views:
Transcription
1 A Fully Integrated Cancer Company. Jefferies Global Healthcare Conference June 3, 2014 Robert Mulroy, President and CEO
2 Forward Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts, they are forwardlooking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include any statements about Merrimack s strategy, future operations, future financial position and future expectations and plans and prospects for Merrimack, and any other statements containing the words anticipate, believe, estimate, expect, intend, may, plan, predict, project, target, potential, will, would, could, should, continue, hope and similar expressions. In this presentation, Merrimack s forward-looking statements include statements about the potential effectiveness and safety profile of Merrimack s product candidates, including MM-398 either alone or in combination, the expected timeline for seeking regulatory approval for the MM-398 combination regimen, Merrimack s ability to translate clinical data into future clinical success, anticipated milestones, including the initiation of new trials, the timing of availability of clinical trial data, the status of and enrollment in clinical trials, the timing of availability of clinical trial data, Merrimack s commercialization plans and strategies and the ability to enter into business development transactions. Such forward-looking statements involve substantial risks and uncertainties that could cause Merrimack's clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the initiation of future clinical trials, availability of data from ongoing clinical trials, expectations for regulatory approvals, development progress of Merrimack's companion diagnostics, availability of funding sufficient for Merrimack s foreseeable and unforeseeable operating expenses and capital expenditure requirements, and other matters that could affect the availability or commercial potential of Merrimack's drug candidates or companion diagnostics. Merrimack undertakes no obligation to update or revise any forward-looking statements. Forward-looking statements should not be relied upon as representing Merrimack's views as of any date subsequent to the date hereof. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Merrimack's business in general, see the Risk Factors section of Merrimack's Annual Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 6, 2014 and other reports Merrimack files with the SEC. 2
3 Investment Highlights MM-398 Achieves Ph3 Endpoint in Pancreatic Cancer Combo arm achieved mos of 6.1 months, HR=0.67, p-value=0.012 Preparing to file NDA Core commercial team preparing for launch MM-121 BM+ data in Ovarian, Breast & NSCLC Pre-specified biomarkers identified 30-50% of patients most at risk of progression BM+ patients showed statistically significant improvement in PFS Technology Leadership Systems biology R&D engine driving new insights into cancer Six novel therapeutics in clinical development with companion Dx Nanoliposomes improve drug deposition and exposure Multispecific antibody capabilities engineering novel agents 3
4 A Superior Approach to Drug Discovery Gene Protein Network Network dynamics govern cell decisions Systems dynamics is a way to evolve our understanding of cancer and our ability to develop targeted therapies Predictive models enable more precise targeting and the development of diagnostics Simulations inform the engineering of drugs and the understanding of their pharmacodynamics Paired with deep technological expertise, this approach enables rapid development of new therapies with a strong clinical rationale 4
5 Drugs Engineered to Specific Cancer Biology PC Phase1 Phase 2 Phase 3 MM-310 undisclosed MM-131 undisclosed DX-929 Nano-imaging agent MM-302 nano-doxorubicin MM-151 EGFR MM-141 IGF1R-ErbB3 MM-121 ErbB3 MM-111 ErbB2-ErbB3 MM-398 nanoirinotecan 5
6 Merrimack s Antibody-targeted Nanoliposomal Drug Platform vs. ADCs 30,000+ drug molecules per nanoliposome Many types of drugs Many options for targeting antigens 2-4 drug molecules per antibody Few drugs possible Very few antigens have proven possible 6
7 NanotherapeuticsDesigned for Protected Delivery and Prolonged Exposure Preclinical Data MM-398: Sustained intra-tumor levels t 1/2 (h) AUC (µg*h/ml) CPT MM Clinical Data PK analysis of patients show extended circulation 70-fold higher AUC in the blood vs. irinotecan Local activation of MM-398 in tumor (AACR 2014) 5-fold higher levels of SN-38 in the tumor compared to blood 7
8 MM-398 Nanoliposomal encapsulation of irinotecan Engineered for increased drug deposition, local activation of SN- 38 and prolonged cytotoxic effects Recently achieved positive phase 3 results in combination arm in pancreatic cancer Next step is to file NDA in 2014 Has orphan drug designation Additional studies ongoing in CRC, Ewing s sarcoma and glioma Imaging diagnostic also in development 8
9 Pancreatic cancer is difficult to treat Tumor Associated Macrophages (TAMs) Associated with poor prognosis Dense stroma Drug penetration barrier Extracellular matrix proteins Complex intracellular signaling pathways Hypoxic micro-environment (Wilson & Hay, 2011) Suppresses cytotoxic drug activity gemcitabine 9
10 MM-398 Ph3Study Design Primary Endpoint: Overall Survival Secondary Endpoints: Progression Free Survival Safety and Adverse Event Profile Metastatic Pancreatic Cancer Received prior gemcitabine-based therapy N = 405 (planned): 417 (actual) RANDOMIZATION Global Principal Investigator: Daniel D. Von Hoff, M.D., F.A.C.P. Arm A: MM mg/m2 IV q 3 weeks Arm B (control): 5-FU/LV 2000 mg/m2 IV over 24 hours/200 mg/m2 l+dracemic form, q weekly X 4 Arm C: MM FU/LV MM mg/m2 IV, q 2 weeks 5-FU/LV 2400 mg/m2 IV over 46 hours/400 mg/m2 l+dracemic form 1:1:1 randomization for paired-wise comparison against 5-FU/LV control arm 10
11 MM-398 Ph3Top line Results MM-398 in combination with 5-FU/LV Median OS 6.1 months HR=0.67; p-value= month improvement over control arm Statistically significant improvement in PFS also observed Control arm 5-FU/LV Median OS 4.2 months MM-398 monotherapy Median OS 4.9 months HR=0.99, p-value=
12 MM-398 Ph3Top line Safety Most common Grade 3 or higher adverse events in the combination arm Neutropenia (14.5%) Fatigue (13.7%) Diarrhea (12.8%) Vomiting (11.1%) Sepsis (3.4%) was the only serious life threatening event that occurred with a more than 2% difference between the combination arm and the control arm In general, patients on the monotherapy arm experienced a higher level of adverse events at this dose and treatment schedule compared to patients who received the combination of MM-398 with 5-FU and leucovorin 12
13 Pancreatic Cancer Landscape Extremely high unmet medical need with few clinical options 73% mortality within one year 6% 5-year survival Unacceptably high recurrence rates post adjuvant treatment (ACS Cancer Facts and Figures 2014) Front line treatment in Pancreatic Cancer FOLFIRINOX: 11.1 mo. vs. GEM mo. (Conroy, NEJM) Abraxane-GEM: 8.5 mo. vs. GEM mo. (Impact, 2013) GEM monotherapy: 5-6 mo. (various) Gemcitabine is the mainstay first line treatment and a significant proportion of patients treated with gemcitabine will be eligible for further treatment. Second line treatment (post-gem) No approved regimens other than 5-FU & leucovorin 13
14 MM-398 Path Forward & Next Steps Regulatory Path: Hold Pre-NDA meeting with FDA Plan to submit NDA in 2014 Commercial Next Steps: Core commercial team preparing for potential launch Activities initially focused on US Geographic clustering allows pancreatic cancer physicians to be effectively targeted by a small, focused field force Expansion/Development: Diagnostic-led expansion into other indications Geographic Location Pancreatic Cancer US ~45,000 EU ~60,000 Japan ~30,000 China ~100,000 Patients Diagnosed Annually* *Decision Resources Report on Pancreatic Cancer. Ma et al. [Trend and prediction on the incidence of pancreatic cancer in China] Feb;34(2): Chinese. 14
15 MM-398 Diagnostic Approach with Ferumoxytol* Pre FMX MRI 24 hours post FMX MRI Presented at AACR 2014 grow 6 patients 23 lesions 5 different tumor types Best Change in Tumor Lesion Size stable *The use of Ferumoxytol(Feraheme, AMAG Pharmaceuticals) in the pilot study mentioned above is for clinical investigational studies only and has not been approved by the FDA. More FMX uptake shrink 15
16 MM-121: Addressing ErbB3-Driven Cancers MM-121 is a monoclonal antibody targeting ErbB3 About ErbB3-Driven Cancer Promotes resistance to therapies and worsens patient outcomes Spans many solid tumors Works in conjunction with other pathways Not a traditional oncogenic pathway where it is primary driver of the cancer # patients MM-121 Designed to Target Biomarker Positive (BM+) patients Unmet need BM+ BM- Response Biomarker positive patients appear to respond worse to standard-of-care (SOC) than biomarker negative patients Biomarker positive patients on MM-121 may respond better than biomarker positive patients on SOC alone 16
17 MM-121 Ph2 Studies: HRG is the Key Biomarker Patients with HRG respond poorly to standard-of-care MM-121 appears to restore sensitivity in HRG positive patients Optimal benefit is observed in HER2 low patients (0+ and 1+) MM-121 This is important to measure in ovarian cancer (~50% of HRG positive patients are HER2 2+) This is NOT important to measure in HER2 negative breast cancer and NSCLC (very few patients are HER2 2+) 17
18 Clinical Testing of Diagnostic Hypothesis Archived Biopsy Platinum-resistant Ovarian Cancer (N=220) Ovarian cancer 140 Paclitaxel + MM-121 Paclitaxel 80 Archived ER/PR+ Metastatic Breast Cancer (N=115) ER/PR+ mbc 59 Exemestane + MM-121 Exemestane 56 Archived Biopsy EGFR wt NSCLC (N=129) EGFR wt NSCLC 85 Erlotinib + MM-121 Erlotinib 44 18
19 MM-121 PFS Data in Biomarker (BM) Defined Population Progression-free survival BM+ Paclitaxel Paclitaxel + MM-121 Ovarian BM+ BM- BM- BM+ BM- BM- Progression-free survival BM+ Exemestane Exemestane + MM-121 Breast Time (weeks) Time (weeks) Progression-free survival BM+ BM+ Erlotinib Erlotinib + MM-121 Lung Study BM+ BM- N HR Prev. N HR Ovarian % Breast % Lung % BM- BM Time (weeks) 19
20 HRG is pervasive & Orthogonal to Other Mechanisms of Disease Ovarian cancer Breast cancer Bladder cancer Cervical cancer 41% 56% 46% 71% Colorectal cancer Head and Neck cancer Liver cancer 36% 99% 55% Prostate cancer 48% SOC Combos Pancreatic cancer Melanoma Uterine cancer Indications 57% 40% 28% HRG expression data from The Cancer Genome Atlas Percentages based on observed threshold for MM-121 benefit in ovarian cancer
21 MM-111 HER2-3 bispecific Ab Engineered against hyperactive HER2/HER3/HRG trimer Demonstrated superior signaling inhibition to current agents in preclinical studies Global Ph2 trial in gastric cancer underway Diagnostic approach: Stratifying based on HER2 and other biomarkers Wholly owned MM Multiple Combinations Phase 1 HER2+ Patients in Multiple Solid Tumors 42% ORR 52% CBR Presented at ESMO 2012 * Indicates patient ongoing at time of presentation The toxicity profile of the MM-111 combinations was consistent with that generally observed in patients receiving the underlying HER2 therapy. 21
22 MM-111 Ph2 Second Line Gastric Study Applied learning from MM-121 Ph2 program Increased confidence in ErbB3 as a target and in its role across solid tumors Added a second independent primary objective for biomarker positive population Updated Study Design Enroll 120 HER2+ FISH+ Patients Focuses resources on biomarker-driven data, increases number of patients studied in this population and is a faster path to proof of concept for MM-111 Data anticipated in 2015 Documentation of HER2 Expression HER2 3+ OR HER2 2+ AND FISH+ 1:1 RANDOMIZATION Experimental (60 patients) Paclitaxel + Trastuzumab + MM-111 Comparator (60 patients) Paclitaxel + Trastuzumab 22
23 progression free survival (PFS) (months) best change in tumor burden (% change) MM-302 ErbB2 Abtargeted nanotherapeutic encapsulation of doxorubicin Engineered for local accumulation & retention (10x) and maximal potency/cell uptake Designed to address cardiotox issues of combinations Diagnostic approach: PET/MRI imaging with copper labeled molecule Wholly owned Phase 1 Monotherapy Presented at SABCS December 2013 N 27 Complete Response (CR) 1 Partial Response (PR) 3 Stable Disease (SD) 6 ORR (CR + PR) 15% CBR (CR + PR + SD) 37% PFS: 5.6 months (95% CI: 2.8, 10.9)
24 MM-302 SABCS 2013 Phase 1 Data CT PET merge Anthracycline Naïve Response Data 44 hr 53 min ROI ROI ROI=RegionofInterest ROI ROI ROI ROI Positron emission tomography/computed tomography (PET/CT) of patients treated with MM-302 and 64 Cu-labeled MM-302 indicates liposomal accumulation in difficult to treat metastatic lesions. Patients were imaged within the first hour and approximately 20 to 48 hours later. A region of interest (ROI) encompassing the site of a brain metastasis for patient , as determined by MRI(not shown), is shown. PET signal enhancement at 44 hours indicates 64 Cu-MM-302deposition. best change in tumor burden (% change) progression free survival (PFS) (months) N 9 CR 1 PR 3 SD 1 ORR 44% CBR 56% PFS: 10.9 months (95% CI: 1.6, NR) 24
25 Other Merrimack ASCO Data MM-151 MM-141 EGFR IGFR ErbB3 Oligoclonalanti-EGFR antibody combination Presented Phase 1 study results Next step: initiation of Ph2 study in colorectal cancer in 2014 Bispecificantibody designed to target IGF-1R and ErbB3 Presented Phase 1 study results Next step: initiation of Ph2 study in front line pancreatic cancer Also presented: MM-111 Ph1 multi-arm study in combination with standard of care therapies in multiple tumor types MM-121 Ph1 study testing safety and pharmacokinetics in patients with advanced solid cancers 25
26 Anticipated Milestones Presentation of full data for MM-398 Ph3 study in pancreatic cancer at ESMO GI in June Top line data for MM-121 Ph2 study in neoadjuvanttnbc in Q2 14 Initiation of Ph2 studies for MM-302, MM-151 and MM-141 in 2014 Business development transactions across pipeline in
27 Investment Highlights MM-398 Achieves Ph3 Endpoint in Pancreatic Cancer Combo arm achieved mos of 6.1 months, HR=0.67, p-value=0.012 Preparing to file NDA Core commercial team preparing for launch MM-121 BM+ data in Ovarian, Breast & NSCLC Pre-specified biomarkers identified 30-50% of patients most at risk of progression BM+ patients showed statistically significant improvement in PFS Technology Leadership Systems biology R&D engine driving new insights into cancer Six novel therapeutics in clinical development with companion Dx Nanoliposomes improve drug deposition and exposure Multispecific antibody capabilities engineering novel agents 27
28 Oncology Pipeline Candidate Design Target Trial (1) Preclin Ph1 Ph2 Ph3 Pre-NDA Signaling Inhibitors Nanoliposomes MM-398 MM-302 MM-310 MM-121 MM-111 MM-151 MM-141 Nanotherapeutic targeted irinotecan ErbB2 Ab targeted nanotherapeutic doxorubicin Antibody targeted nanotherapeutic Monoclonal antibody Bispecific antibody Oligoclonal antibody Bispecific tetravalent antibody Topo I inhibition / DNA replication Topo II inhibition / DNA replication Undisclosed ErbB3 ErbB3 & ErbB2 EGFR IGF-1R & ErbB3 Ph2 mono: 25% 1 yr OS 5.2 mos median OS 50% DCR Ph1 mono: 15% ORR 37% CBR N/A Ph1 combo: 39% ORR 70% CBR Ph1 combo: 40% ORR 52% CBR Ph1 mono: TBA Ph1 mono: TBA MM-131 Multispecific antibody Undisclosed N/A (1) Selected trials: MM-121 plus paclitaxel in ErbB2 (HER2) negative breast, ovarian and other gynecological cancers; MM-111 plus multiple anti-cancer therapies in ErbB2 (HER2) positive solid tumors; MM-398 monotherapy in pancreatic cancer; MM-302 monotherapy in ErbB2 (HER2) positive breast cancer 28
A Fully Integrated Cancer Company.
A Fully Integrated Cancer Company. Jefferies 2015 Healthcare Conference June 2, 2015 Robert Mulroy, President & CEO Forward Looking Statements To the extent that statements contained in this presentation
More informationMerrimack Pharmaceuticals: A Refocused R&D Company January 2017
Merrimack Pharmaceuticals: A Refocused R&D Company January 2017 Forward Looking Statements This presentation contains forward-looking statements of the Company that involve substantial risks and uncertainties.
More informationCorporate Overview. May 2017 NASDAQ: CYTR
Corporate Overview May 2017 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationCorporate Overview. July 2016 NASDAQ: CYTR
Corporate Overview July 2016 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES ASSOCIATED WITH A DEVELOPMENT-STAGE
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationVeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show
More informationGenta Incorporated. A Multiproduct Late-Stage Oncology Company
Genta Incorporated A Multiproduct Late-Stage Oncology Company This presentation may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationInvestor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer.
Investor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer November 8, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation
More informationIMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationSTUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER
Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationREWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES
REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES May 18, 2017 Molecularly Defined Solid Tumor Program Update FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations,
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationCorporate Overview. September 2018
Corporate Overview September 2018 Forward Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts, they are forward-looking statements reflecting
More informationVAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
More informationLeading the Next Wave of Biotech Breakthroughs
Leading the Next Wave of Biotech Breakthroughs Corporate Extensive corporate assets Platforms Pipeline Partnerships Building a sustainable global business Platform licenses represent a source of non-dilutive
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking
More informationMERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018
MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward
More informationMERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018
MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More informationBuilding a Premier Oncology Biotech
Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationSpectrum Pharmaceuticals
Spectrum Pharmaceuticals Joe Turgeon President and CEO June 2018 Investor Presentation 1 Safe Harbor Statement This presentation contains forward looking statements regarding future events and the future
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer March 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may
More informationMerck ASCO 2015 Investor Briefing
Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
More informationMarch Corporate Presentation
March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements
More informationBuilding a Premier Oncology Biotech
Building a Premier Oncology Biotech August 208 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within
More informationAVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationCorporate Overview. June 2018 NASDAQ:FPRX
Corporate Overview June 2018 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2015 Global Healthcare Conference Peter P. Pfreundschuh, VP Finance and CFO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2015 Global Healthcare Conference Peter P. Pfreundschuh, VP Finance and CFO Forward-Looking Statements This
More informationCorporate Presentation
Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y Forward Looking Statements / Safe Harbor This presentation contains
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationAnalyst/Investor Call
Analyst/Investor Call November 20 th, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations
More informationInvestor Presentation
Investor Presentation June 2017 Joe Turgeon President and Chief Operating Officer Safe Harbor Statement This presentation contains forward-looking statements regarding future events and the future performance
More informationTARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018
NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements
More informationMANIFEST Phase 2 Enhancement / Expansion
MANIFEST Phase 2 Enhancement / Expansion Investor Conference Call Stellar Science, Breakthrough Medicine October 11, 2018 Forward-Looking Statements This presentation contains forward-looking statements
More informationRexahn Pharmaceuticals Overview
Rexahn Pharmaceuticals Overview May 2018 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn s actual results may differ
More informationFORWARD II PROGRAM UPDATE
FORWARD II PROGRAM UPDATE NASDAQ: IMGN May 17, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements based on management's current expectations. These statements include,
More informationLonnie Moulder, CEO Leerink Global Healthcare Conference February 12, 2015
Lonnie Moulder, CEO Leerink Global Healthcare Conference February 12, 2015 Safe Harbor Statement Statements made in this presentation about TESARO, Inc. that are not descriptions of historical facts are
More informationPLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective
PLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective Davy Chiodin, VP - Regulatory Science, QA and Compliance, Acerta Pharma (A Member of the AstraZeneca
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationCase 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?
Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old
More informationNewLink Genetics Corporation
Cantor Fitzgerald 2018 Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK October 3, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking
More informationSafe Harbor Statement
Safe Harbor Statement This document may include statements that constitute forward looking statements, which are often characterized by the terms may, believes, expects or anticipates and do not reflect
More informationASCO 2018 Investor Meeting
ASCO 2018 Investor Meeting June 4, 2018 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationArQule CorporateUpdate
ArQule April 2015 1 ArQule CorporateUpdate Safe Harbor This presentation and other statements by ArQule may contain forwardlooking statements within the meaning of the Private Securities Litigation Reform
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More informationARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc. June 8, 2016 David Sachs Non-small cell lung cancer 1 ARIAD clinical trial patient Some of the statements in this presentation constitute forward looking statements under the
More informationAACR 2018 Investor Meeting
AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationMerck Oncology Overview ASCO 2017
Merck Oncology Overview ASCO 217 June 5, 217 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, NJ, USA (the company ) includes forward-looking
More informationMerck Oncology Overview ASCO 2017
Merck Oncology Overview ASCO 217 June 5, 217 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, NJ, USA (the company ) includes forward-looking
More informationNY-ESO SPEAR T-cells in Synovial Sarcoma
NY-ESO SPEAR T-cells in Synovial Sarcoma ASCO Update June 6, 2017 Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform
More informationDetermined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019
Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019 Forward-looking statements disclosure This presentation contains
More informationFirst Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented
More informationPositioned for Growth
Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation
More informationJefferies Global Healthcare Conference New York 2014
Jefferies Global Healthcare Conference New York 2014 Disclaimer This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other
More information2016 Year-End Results and Conference Call. March 14, 2017
2016 Year-End Results and Conference Call March 14, 2017 Forward Looking Statement This communication contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform
More informationAdjuvant therapy in pancreatic cancer Monotherapy for whom? JL VAN LAETHEM, MD,PhD
Adjuvant therapy in pancreatic cancer Monotherapy for whom? JL VAN LAETHEM, MD,PhD Efficacy Parameters in adjuvant monochemotherapy Randomized studies in resectable PDAC Regimen DFS HR (p) OS HR (p) 5-yr-OS
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More information-- Single Global Phase 3 Trial Expected to Begin in First Half of
Catabasis Pharmaceuticals Reports Edasalonexent Preserved Muscle Function and Substantially Slowed Duchenne Muscular Dystrophy Disease Progression Through More Than One Year of Treatment -- Consistent
More informationESMO 2016 * Investor Meeting October 9, *European Society of Medical Oncology, October 7-11, 2016 ESMO 2016 NOT FOR PRODUCT PROMOTIONAL USE
ESMO 2016 * Investor Meeting October 9, 2016 *European Society of Medical Oncology, October 7-11, 2016 1 Forward-Looking Information During this meeting, we will make statements about the Company s future
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More informationQ Financial Update November 6, 2018 NASDAQ:FPRX
Q3 2018 Financial Update November 6, 2018 NASDAQ:FPRX 2 Forward-Looking Statements Disclaimer Forward-looking statements contained in this presentation include statements regarding (i) the timing of initiation,
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
More informationDetermined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017
Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017 1 Forward-looking statements disclosure This presentation contains
More informationG1 Corporate Overview March 11, 2019
G1 Corporate Overview March 11, 2019 www.g1therapeutics.com NASDAQ: GTHX 1 Forward-looking statements This presentation and the accompanying oral commentary contain forward-looking statements within the
More informationClovis Oncology Announces First Quarter 2017 Operating Results. May 3, :06 PM ET
Clovis Oncology Announces First Quarter 2017 Operating Results May 3, 2017 4:06 PM ET Strong Q1 launch quarter for Rubraca (rucaparib) in U.S. with $7M reported in net sales Clovis notified that ARIEL3
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationDetermined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017
Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017 1 Forward-looking statements disclosure This presentation contains forward-looking
More informationClovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET
Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2017 EARNINGS PRESENTATION MARCH 2018 1 Forward-looking statements disclosure This presentation contains
More informationCytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer
November 26, 2018 CytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer VANCOUVER, Washington, Nov. 26, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc.
More informationCompany Overview. April Rewriting cancer treatment NASDAQ: EPZM
Company Overview NASDAQ: EPZM Rewriting cancer treatment Forward Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform
More informationFull Year 2017 Financial Results. February 14, 2018
Full Year 2017 Financial Results February 14, 2018 Agios Conference Call Participants Prepared Remarks Introduction KENDRA ADAMS, Sr. Director, Investor Relations 2018 Vision & Key Milestones DAVID SCHENKEIN,
More informationCorporate Presentation: Jefferies Global Healthcare Conference June 7, 2018
Corporate Presentation: Jefferies Global Healthcare Conference June 7, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More informationOverview. What s New in the Treatment of Pancreatic Cancer? Lots! Steven J. Cohen, M.D. Fox Chase Cancer Center September 17, 2013
What s New in the Treatment of Pancreatic Cancer? Lots! Steven J. Cohen, M.D. Fox Chase Cancer Center September 17, 2013 Overview Staging and Workup Resectable Disease Surgery Adjuvant therapy Locally
More information-- Edasalonexent Substantially Slowed Duchenne Muscular Dystrophy Disease Progression through 36 Weeks --
Catabasis Pharmaceuticals Reports Positive Results from Open-Label Extension of Phase 2 MoveDMD Trial Evaluating Edasalonexent in Duchenne Muscular Dystrophy and Plans to Initiate Phase 3 Clinical Trial
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationReimagining Cancer Treatment. Determined to realize a future in which people with cancer live longer and better than ever before
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Cantor Fitzgerald 2nd Annual Healthcare Conference July 13, 2016 Forward-Looking
More informationSavolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer
Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer Initiation of expanded Phase II trials in NSCLC triggers US$10 million milestone from AstraZeneca to Chi-Med New study
More informationJefferies 2015 Healthcare Conference
Jefferies 2015 Healthcare Conference Paul J. Hastings Chairman and Chief Executive Officer June 2, 2015 Safe Harbor Statement These slides and accompanying oral presentation contain forward-looking statements.
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More information